Touch Medical Media Services's video: Jesus G Berdeja ASCO20: Updated Results from the Phase Ib II CARTITUDE-1 Trial

Jesus G Berdeja, Director of myeloma research at Sarah Cannon Research Institute, discusses the updated results from the Phase Ib/II CARTITUDE-1 trial, which were presented at ASCO20. The study assesses the efficacy and safety of CAR-T treatment JNJ-4528 in heavily pre-treated patients with multiple myeloma. Questions 1. What are the current unmet needs in CAR-T therapy? (0:06) 2. Could you give us a brief description of JNJ-4528 and how it differs from current CAR-T therapies? (0:32) 3. Could you tell us a little about the CARTITUDE-1 study and its efficacy findings? (1:10) 4. What were the safety findings in terms of cytokine release syndrome and neurotoxicity? (3:00) 5. What will be the next steps in the clinical development of JNJ-4528? (4:05) Speaker disclosure: Jesus G Bordeja receives institution research funds from Abbvie, Amgen, Acetylon, Bluebird, BMS, Celgene, Celularity, Constellation, CRISP Therapeutics, CURIS, EMD Sorono, Genentech, Glenmark, Janssen, Kesios, Lilly, Novartis, Poseida, Sanofi, Takeda, Teva and Vivolux. His institution receives consultancy payments from Amgen, BioClinica, BMS, Celgene, CRISPR Therapeutics, Janssen, Karyopharm, Kite Pharma, Legend, Prothena, SecuraBio, Servier and Takeda. Support: Interview and filming supported by Touch Medical Media. Commissioned in liaison with Edelman. Filmed in coverage of the 2020 ASCO Virtual Scientific Program.